Pfizer: Covid vaccine 90% effective in late-stage study
(CercleFinance.com) - Pfizer and German partner BioNTech said that their experimental vaccine against Covid-19 has been found to be over 90%-effective in the first interim analysis of a late-stage study.
The Phase 3 clinical trial - which began in late July - has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine, the companies said.
In another piece of good news, the external, independent monitoring committee which conducted the analysis has not reported any serious safety concerns and recommends that the study continue, Pfizer and BioNTech said.
The drugmakers said they are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the quality of their vaccine.
Based on current projections they expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Phase 3 clinical trial - which began in late July - has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine, the companies said.
In another piece of good news, the external, independent monitoring committee which conducted the analysis has not reported any serious safety concerns and recommends that the study continue, Pfizer and BioNTech said.
The drugmakers said they are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the quality of their vaccine.
Based on current projections they expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.